Potential conflict of interest: nothing to report.
Is the FXR the fix for cholesterol gallstone disease?†
Article first published online: 16 JUN 2005
Copyright © 2005 American Association for the Study of Liver Diseases
Volume 42, Issue 1, pages 218–221, July 2005
How to Cite
Juran, B. D. and Lazaridis, K. N. (2005), Is the FXR the fix for cholesterol gallstone disease?. Hepatology, 42: 218–221. doi: 10.1002/hep.20776
- Issue published online: 16 JUN 2005
- Article first published online: 16 JUN 2005
Cholesterol gallstone disease is characterized by several events, including cholesterol precipitation in bile, increased bile salt hydrophobicity and gallbladder inflammation. Here, we describe the same phenotype in mice lacking the bile acid receptor, FXR. Furthermore, in susceptible wild-type mice that recapitulate human cholesterol gallstone disease, treatment with a synthetic FXR agonist prevented sequelae of the disease. These effects were mediated by FXR-dependent increases in biliary bile salt and phospholipid concentrations, which restored cholesterol solubility and thereby prevented gallstone formation. Taken together, these results indicate that FXR is a promising therapeutic target for treating or preventing cholesterol gallstone disease.